Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
Akero Therapeutics (Nasdaq: AKRO) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 9:10 a.m. ET. The presentation will be accessible through a live webcast via the investor relations section of Akero's website at www.akerotx.com, with an archived replay available afterward. Akero is a clinical-stage company focused on developing treatments for serious metabolic diseases with high unmet medical needs.
Akero Therapeutics (Nasdaq: AKRO) ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore ISI HealthCONx. La direzione dell'azienda parteciperà a una chiacchierata informale martedì 3 dicembre 2024, alle 9:10 ET. La presentazione sarà accessibile tramite un webcast dal vivo nella sezione dedicata alle relazioni con gli investitori del sito web di Akero all'indirizzo www.akerotx.com, con una registrazione disponibile successivamente. Akero è un'azienda in fase clinica concentrata nello sviluppo di trattamenti per gravi malattie metaboliche con elevate esigenze mediche non soddisfatte.
Akero Therapeutics (Nasdaq: AKRO) ha anunciado su participación en la 7ª Conferencia Anual Evercore ISI HealthCONx. La dirección de la empresa participará en una charla informal el martes 3 de diciembre de 2024, a las 9:10 a.m. ET. La presentación será accesible a través de una transmisión en vivo por webcast en la sección de relaciones con inversionistas del sitio web de Akero en www.akerotx.com, con una repetición archivada disponible posteriormente. Akero es una empresa en etapa clínica centrada en desarrollar tratamientos para enfermedades metabólicas graves con altas necesidades médicas no satisfechas.
Akero Therapeutics (Nasdaq: AKRO)는 제7회 Evercore ISI HealthCONx 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진은 2024년 12월 3일 화요일 오전 9시 10분 ET에 대화형 토크에 참여할 예정입니다. 발표는 Akero 웹사이트의 투자자 관계 섹션을 통해 라이브 웹캐스트로 이용 가능하며, 이후 아카이브 재생도 제공될 것입니다. Akero는 치료가 시급한 심각한 대사 질환을 위한 치료제를 개발하는 데 집중하는 임상 단계의 회사입니다.
Akero Therapeutics (Nasdaq: AKRO) a annoncé sa participation à la 7ème Conférence Annuelle Evercore ISI HealthCONx. La direction de l'entreprise participera à une discussion informelle le mardi 3 décembre 2024, à 9h10 ET. La présentation sera accessible via un webcast en direct dans la section des relations investisseurs du site Web d'Akero à l'adresse www.akerotx.com, avec une rediffusion archivée disponible par la suite. Akero est une entreprise en phase clinique axée sur le développement de traitements pour des maladies métaboliques graves présentant de grands besoins médicaux non satisfaits.
Akero Therapeutics (Nasdaq: AKRO) hat seine Teilnahme an der 7. jährlichen Evercore ISI HealthCONx-Konferenz bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 3. Dezember 2024, um 9:10 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Live-Webcast im Bereich Investor Relations auf der Website von Akero unter www.akerotx.com zugänglich sein, mit einer späteren Archivwiedergabe. Akero ist ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für schwere Stoffwechselerkrankungen mit hohen unerfüllten medizinischen Bedürfnissen konzentriert.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 9:10 a.m. ET.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero’s lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH (F2-F3) or compensated cirrhosis (F4) due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the completed HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the ongoing SYMMETRY study in patients with compensated cirrhosis (F4) due to MASH, in which more than 300 patients have been treated with EFX or placebo for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the Evercore ISI HealthCONx Conference 2024?
How can investors watch Akero Therapeutics' (AKRO) presentation at the HealthCONx Conference?
What type of presentation will Akero Therapeutics (AKRO) give at the 2024 HealthCONx Conference?
What is the focus area of Akero Therapeutics (AKRO) as presented in the announcement?
